A first-in-human Phase I trial in patients with advanced solid tumors (mainly biliary tract and pancreatic cancers) found that JPH203 was generally well tolerated; the dose-limiting toxicity was a reversible elevation of bilirubin, likely due to on-target effects of LAT1 inhibition in liver cells (LAT1 helps transport bilirubin conjugates) [97]. Here, SLC7A5 is linked to pancreatic neoplasm.